Henlius Biotech wins shareholder approval for Star dual listing

By Jonathan Breen
31 Mar 2020

Hong Kong-listed Shanghai Henlius Biotech got the go ahead from its controlling shareholders on Monday for a secondary flotation on China’s Star Market.

The biopharmaceutical company is a subsidiary of Shanghai Fosun Pharmaceutical, which is controlled by Fosun International. Both are HKEX-listed companies and hold a combined indirect 53% stake in Shanghai Henlius.

The subsidiary listed on the HKEX in September last year through a HK$3.21bn ($414m) spin-off by Fosun ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.